Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus™.
Key improvements include:
- New formulation models for advanced technologies, including long-acting injectable options developed through the funded collaboration with the U.S. FDA
- New models for in vitro biorelevant dissolution experiments, including Artificial Stomach and Duodenum (ASD), Biphasic, and Membrane systems
- Enhanced multistage dissolution capabilities to guide improved in vitro-in vivo correlation (IVIVC) development with GastroPlus®
- Improved options for modeling precipitation kinetics
- And more …
Dr. Viera Lukacova, director of simulation sciences, said: “Our users asked us to accelerate development of new approaches to help them in their ongoing quest to extrapolate key insights from in vitro experiments. With the release of version 6, our talented team of scientists and engineers developed unique mathematical models that no other in silico tool offers and validated them for different applications, especially related to the interplay between dissolution, precipitation, and absorption kinetics.”
John DiBella, president of the Lancaster division, added: “The DDDPlus client base has steadily increased over the years, with several regulatory agencies now using the program to assess dissolution method and product specification questions. We are especially excited about the improved functionality and synergies between this new release of DDDPlus and GastroPlus. Version 6 will offer users one-of-a-kind approaches that better inform their in vivo predictions and allow them to make formulation development decisions with confidence. I am proud of the advances we have made and look forward to having users apply this to their day-to-day research.”
An in-depth webinar showcasing the new features in DDDPlus can be streamed on the company website.